CN1199567C - 混合基质植入物和外植物 - Google Patents
混合基质植入物和外植物 Download PDFInfo
- Publication number
- CN1199567C CN1199567C CNB961993243A CN96199324A CN1199567C CN 1199567 C CN1199567 C CN 1199567C CN B961993243 A CNB961993243 A CN B961993243A CN 96199324 A CN96199324 A CN 96199324A CN 1199567 C CN1199567 C CN 1199567C
- Authority
- CN
- China
- Prior art keywords
- cells
- collagen
- article
- cell
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000011159 matrix material Substances 0.000 title claims abstract description 139
- 239000007943 implant Substances 0.000 title claims description 17
- 239000004005 microsphere Substances 0.000 claims abstract description 121
- 102000008186 Collagen Human genes 0.000 claims abstract description 118
- 108010035532 Collagen Proteins 0.000 claims abstract description 118
- 229920001436 collagen Polymers 0.000 claims abstract description 118
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims abstract description 40
- 239000011521 glass Substances 0.000 claims abstract description 16
- 239000004793 Polystyrene Substances 0.000 claims abstract description 14
- 239000000463 material Substances 0.000 claims abstract description 14
- 229920002223 polystyrene Polymers 0.000 claims abstract description 14
- 235000010410 calcium alginate Nutrition 0.000 claims abstract description 8
- 239000000648 calcium alginate Substances 0.000 claims abstract description 8
- 229960002681 calcium alginate Drugs 0.000 claims abstract description 8
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 claims abstract description 8
- 239000004816 latex Substances 0.000 claims abstract description 8
- 229920000126 latex Polymers 0.000 claims abstract description 8
- 229920002492 poly(sulfone) Polymers 0.000 claims abstract description 8
- 229920002401 polyacrylamide Polymers 0.000 claims abstract description 8
- 229920002678 cellulose Polymers 0.000 claims abstract description 7
- 239000001913 cellulose Substances 0.000 claims abstract description 7
- 229920002307 Dextran Polymers 0.000 claims abstract 5
- 210000004027 cell Anatomy 0.000 claims description 205
- 239000000203 mixture Substances 0.000 claims description 79
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 49
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 49
- 229920001184 polypeptide Polymers 0.000 claims description 47
- 239000000243 solution Substances 0.000 claims description 35
- 238000000034 method Methods 0.000 claims description 31
- 108090000623 proteins and genes Proteins 0.000 claims description 25
- 238000004519 manufacturing process Methods 0.000 claims description 21
- 238000002360 preparation method Methods 0.000 claims description 20
- 239000000126 substance Substances 0.000 claims description 20
- -1 antibodies Proteins 0.000 claims description 16
- 238000002156 mixing Methods 0.000 claims description 16
- 108020004414 DNA Proteins 0.000 claims description 15
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 15
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 14
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 claims description 14
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 claims description 14
- 239000000835 fiber Substances 0.000 claims description 14
- 210000002950 fibroblast Anatomy 0.000 claims description 14
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 14
- 230000014509 gene expression Effects 0.000 claims description 13
- 241001465754 Metazoa Species 0.000 claims description 11
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims description 10
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 10
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 claims description 10
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 claims description 10
- 229920001343 polytetrafluoroethylene Polymers 0.000 claims description 10
- 239000004810 polytetrafluoroethylene Substances 0.000 claims description 10
- 102000004169 proteins and genes Human genes 0.000 claims description 10
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 9
- 239000002870 angiogenesis inducing agent Substances 0.000 claims description 9
- 239000003102 growth factor Substances 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 9
- 102000012422 Collagen Type I Human genes 0.000 claims description 8
- 108010022452 Collagen Type I Proteins 0.000 claims description 8
- 229920000954 Polyglycolide Polymers 0.000 claims description 8
- 108010009583 Transforming Growth Factors Proteins 0.000 claims description 8
- 102000009618 Transforming Growth Factors Human genes 0.000 claims description 8
- 239000000654 additive Substances 0.000 claims description 8
- 235000010443 alginic acid Nutrition 0.000 claims description 8
- 229920000615 alginic acid Polymers 0.000 claims description 8
- 210000004369 blood Anatomy 0.000 claims description 8
- 239000008280 blood Substances 0.000 claims description 8
- 239000004633 polyglycolic acid Substances 0.000 claims description 8
- 102000004877 Insulin Human genes 0.000 claims description 7
- 108090001061 Insulin Proteins 0.000 claims description 7
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims description 7
- 230000000996 additive effect Effects 0.000 claims description 7
- 229960005070 ascorbic acid Drugs 0.000 claims description 7
- 235000010323 ascorbic acid Nutrition 0.000 claims description 7
- 239000011668 ascorbic acid Substances 0.000 claims description 7
- 239000011324 bead Substances 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 238000011534 incubation Methods 0.000 claims description 7
- 229940125396 insulin Drugs 0.000 claims description 7
- 238000007920 subcutaneous administration Methods 0.000 claims description 7
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 6
- 229920000936 Agarose Polymers 0.000 claims description 6
- 102100022641 Coagulation factor IX Human genes 0.000 claims description 6
- 102000016942 Elastin Human genes 0.000 claims description 6
- 108010014258 Elastin Proteins 0.000 claims description 6
- 108010076282 Factor IX Proteins 0.000 claims description 6
- 102000009123 Fibrin Human genes 0.000 claims description 6
- 108010073385 Fibrin Proteins 0.000 claims description 6
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 6
- 108010067306 Fibronectins Proteins 0.000 claims description 6
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 6
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 6
- 229920002971 Heparan sulfate Polymers 0.000 claims description 6
- 102000007330 LDL Lipoproteins Human genes 0.000 claims description 6
- 108010007622 LDL Lipoproteins Proteins 0.000 claims description 6
- 108090000445 Parathyroid hormone Proteins 0.000 claims description 6
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 claims description 6
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 6
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 6
- 229920002549 elastin Polymers 0.000 claims description 6
- 210000002889 endothelial cell Anatomy 0.000 claims description 6
- 229960004222 factor ix Drugs 0.000 claims description 6
- 229950003499 fibrin Drugs 0.000 claims description 6
- 229920002674 hyaluronan Polymers 0.000 claims description 6
- 229960003160 hyaluronic acid Drugs 0.000 claims description 6
- 229920000728 polyester Polymers 0.000 claims description 6
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 6
- 102000002265 Human Growth Hormone Human genes 0.000 claims description 5
- 108010000521 Human Growth Hormone Proteins 0.000 claims description 5
- 239000000854 Human Growth Hormone Substances 0.000 claims description 5
- 230000001105 regulatory effect Effects 0.000 claims description 5
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 5
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 claims description 4
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims description 4
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims description 4
- 102000055006 Calcitonin Human genes 0.000 claims description 4
- 108060001064 Calcitonin Proteins 0.000 claims description 4
- 229920000742 Cotton Polymers 0.000 claims description 4
- 229920000045 Dermatan sulfate Polymers 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 108010017544 Glucosylceramidase Proteins 0.000 claims description 4
- 102000004547 Glucosylceramidase Human genes 0.000 claims description 4
- 108060003951 Immunoglobulin Proteins 0.000 claims description 4
- 102000014150 Interferons Human genes 0.000 claims description 4
- 108010050904 Interferons Proteins 0.000 claims description 4
- 108010063738 Interleukins Proteins 0.000 claims description 4
- 102000015696 Interleukins Human genes 0.000 claims description 4
- 108010025020 Nerve Growth Factor Proteins 0.000 claims description 4
- 102000015336 Nerve Growth Factor Human genes 0.000 claims description 4
- 239000004677 Nylon Substances 0.000 claims description 4
- 102000007000 Tenascin Human genes 0.000 claims description 4
- 108010008125 Tenascin Proteins 0.000 claims description 4
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 claims description 4
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 claims description 4
- 229940024142 alpha 1-antitrypsin Drugs 0.000 claims description 4
- 239000003114 blood coagulation factor Substances 0.000 claims description 4
- 229960004015 calcitonin Drugs 0.000 claims description 4
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims description 4
- 230000003197 catalytic effect Effects 0.000 claims description 4
- 102000018358 immunoglobulin Human genes 0.000 claims description 4
- 229940079322 interferon Drugs 0.000 claims description 4
- 229940053128 nerve growth factor Drugs 0.000 claims description 4
- 229920001778 nylon Polymers 0.000 claims description 4
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 4
- 239000004626 polylactic acid Substances 0.000 claims description 4
- 239000004800 polyvinyl chloride Substances 0.000 claims description 4
- 229920000915 polyvinyl chloride Polymers 0.000 claims description 4
- 102000007644 Colony-Stimulating Factors Human genes 0.000 claims description 3
- 108010071942 Colony-Stimulating Factors Proteins 0.000 claims description 3
- 101800003838 Epidermal growth factor Proteins 0.000 claims description 3
- 102000016267 Leptin Human genes 0.000 claims description 3
- 108010092277 Leptin Proteins 0.000 claims description 3
- 101710172711 Structural protein Proteins 0.000 claims description 3
- 102000040945 Transcription factor Human genes 0.000 claims description 3
- 108091023040 Transcription factor Proteins 0.000 claims description 3
- 101800004564 Transforming growth factor alpha Proteins 0.000 claims description 3
- 102400001320 Transforming growth factor alpha Human genes 0.000 claims description 3
- 210000001789 adipocyte Anatomy 0.000 claims description 3
- 239000000427 antigen Substances 0.000 claims description 3
- 102000036639 antigens Human genes 0.000 claims description 3
- 108091007433 antigens Proteins 0.000 claims description 3
- 210000001130 astrocyte Anatomy 0.000 claims description 3
- 210000004413 cardiac myocyte Anatomy 0.000 claims description 3
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 claims description 3
- 229940051593 dermatan sulfate Drugs 0.000 claims description 3
- 229940116977 epidermal growth factor Drugs 0.000 claims description 3
- 210000002919 epithelial cell Anatomy 0.000 claims description 3
- 210000004907 gland Anatomy 0.000 claims description 3
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 3
- 229940088597 hormone Drugs 0.000 claims description 3
- 239000005556 hormone Substances 0.000 claims description 3
- 210000002510 keratinocyte Anatomy 0.000 claims description 3
- 229940039781 leptin Drugs 0.000 claims description 3
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims description 3
- 210000002569 neuron Anatomy 0.000 claims description 3
- 239000002243 precursor Substances 0.000 claims description 3
- 150000003180 prostaglandins Chemical class 0.000 claims description 3
- 210000000329 smooth muscle myocyte Anatomy 0.000 claims description 3
- 210000002948 striated muscle cell Anatomy 0.000 claims description 3
- 229960005486 vaccine Drugs 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 2
- 102000013275 Somatomedins Human genes 0.000 claims description 2
- 210000004204 blood vessel Anatomy 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000003292 glue Substances 0.000 claims description 2
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 claims 10
- 102000004127 Cytokines Human genes 0.000 claims 8
- 108090000695 Cytokines Proteins 0.000 claims 8
- 102100033237 Pro-epidermal growth factor Human genes 0.000 claims 8
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims 6
- 102000009840 Angiopoietins Human genes 0.000 claims 6
- 108010009906 Angiopoietins Proteins 0.000 claims 6
- 229940072056 alginate Drugs 0.000 claims 6
- 239000000499 gel Substances 0.000 claims 6
- 230000001737 promoting effect Effects 0.000 claims 6
- 108010041308 Endothelial Growth Factors Proteins 0.000 claims 4
- 102000003951 Erythropoietin Human genes 0.000 claims 4
- 108090000394 Erythropoietin Proteins 0.000 claims 4
- 108091029865 Exogenous DNA Proteins 0.000 claims 4
- 108010054218 Factor VIII Proteins 0.000 claims 4
- 102000001690 Factor VIII Human genes 0.000 claims 4
- 102100037362 Fibronectin Human genes 0.000 claims 4
- 101710098940 Pro-epidermal growth factor Proteins 0.000 claims 4
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 4
- 229940105423 erythropoietin Drugs 0.000 claims 4
- 229960000301 factor viii Drugs 0.000 claims 4
- 210000005260 human cell Anatomy 0.000 claims 4
- 108091008819 oncoproteins Proteins 0.000 claims 4
- 102000027450 oncoproteins Human genes 0.000 claims 4
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims 4
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 claims 3
- 102100037852 Insulin-like growth factor I Human genes 0.000 claims 3
- 230000002378 acidificating effect Effects 0.000 claims 3
- 230000003213 activating effect Effects 0.000 claims 3
- 206010048768 Dermatosis Diseases 0.000 claims 2
- 208000003098 Ganglion Cysts Diseases 0.000 claims 2
- 102000010789 Interleukin-2 Receptors Human genes 0.000 claims 2
- 108010038453 Interleukin-2 Receptors Proteins 0.000 claims 2
- 108010001831 LDL receptors Proteins 0.000 claims 2
- GWNVDXQDILPJIG-SHSCPDMUSA-N Leukotriene C4 Natural products CCCCCC=C/CC=C/C=C/C=C/C(SCC(NC(=O)CCC(N)C(=O)O)C(=O)NCC(=O)O)C(O)CCCC(=O)O GWNVDXQDILPJIG-SHSCPDMUSA-N 0.000 claims 2
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 claims 2
- 102100036893 Parathyroid hormone Human genes 0.000 claims 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims 2
- 208000005400 Synovial Cyst Diseases 0.000 claims 2
- 102100033740 Tenomodulin Human genes 0.000 claims 2
- 101710114852 Tenomodulin Proteins 0.000 claims 2
- 239000002729 catgut Substances 0.000 claims 2
- 210000001612 chondrocyte Anatomy 0.000 claims 2
- 229940047120 colony stimulating factors Drugs 0.000 claims 2
- 230000003511 endothelial effect Effects 0.000 claims 2
- 239000012530 fluid Substances 0.000 claims 2
- 102000034356 gene-regulatory proteins Human genes 0.000 claims 2
- 108091006104 gene-regulatory proteins Proteins 0.000 claims 2
- 210000003494 hepatocyte Anatomy 0.000 claims 2
- 210000003292 kidney cell Anatomy 0.000 claims 2
- 229940091348 latex Drugs 0.000 claims 2
- GWNVDXQDILPJIG-NXOLIXFESA-N leukotriene C4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O GWNVDXQDILPJIG-NXOLIXFESA-N 0.000 claims 2
- 210000003098 myoblast Anatomy 0.000 claims 2
- 210000000963 osteoblast Anatomy 0.000 claims 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 claims 2
- 210000002706 plastid Anatomy 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 230000004936 stimulating effect Effects 0.000 claims 2
- 230000002792 vascular Effects 0.000 claims 2
- OEANUJAFZLQYOD-CXAZCLJRSA-N (2r,3s,4r,5r,6r)-6-[(2r,3r,4r,5r,6r)-5-acetamido-3-hydroxy-2-(hydroxymethyl)-6-methoxyoxan-4-yl]oxy-4,5-dihydroxy-3-methoxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](OC)O[C@H](CO)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](OC)[C@H](C(O)=O)O1 OEANUJAFZLQYOD-CXAZCLJRSA-N 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 210000003714 granulocyte Anatomy 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000007913 intrathecal administration Methods 0.000 claims 1
- 238000007914 intraventricular administration Methods 0.000 claims 1
- 239000002609 medium Substances 0.000 description 32
- 238000012360 testing method Methods 0.000 description 23
- 210000002966 serum Anatomy 0.000 description 22
- 239000001963 growth medium Substances 0.000 description 18
- 238000002474 experimental method Methods 0.000 description 16
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 15
- 210000001519 tissue Anatomy 0.000 description 15
- 239000006052 feed supplement Substances 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 230000001413 cellular effect Effects 0.000 description 12
- 239000013612 plasmid Substances 0.000 description 11
- 239000012634 fragment Substances 0.000 description 10
- 244000309466 calf Species 0.000 description 9
- 239000006285 cell suspension Substances 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 230000029087 digestion Effects 0.000 description 7
- 238000002513 implantation Methods 0.000 description 7
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 6
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 230000001186 cumulative effect Effects 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 238000003153 stable transfection Methods 0.000 description 6
- 238000001890 transfection Methods 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 5
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 5
- 101000969137 Mus musculus Metallothionein-1 Proteins 0.000 description 5
- 238000011081 inoculation Methods 0.000 description 5
- 238000004062 sedimentation Methods 0.000 description 5
- 102000029816 Collagenase Human genes 0.000 description 4
- 108060005980 Collagenase Proteins 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 241000699660 Mus musculus Species 0.000 description 4
- 102000003982 Parathyroid hormone Human genes 0.000 description 4
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 4
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 4
- 239000000512 collagen gel Substances 0.000 description 4
- 229960002424 collagenase Drugs 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 239000002054 inoculum Substances 0.000 description 4
- 238000011580 nude mouse model Methods 0.000 description 4
- 239000000199 parathyroid hormone Substances 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Substances OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 239000013587 production medium Substances 0.000 description 4
- 238000003127 radioimmunoassay Methods 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 229960000187 tissue plasminogen activator Drugs 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 102100022987 Angiogenin Human genes 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- 229920001503 Glucan Polymers 0.000 description 3
- 241001045988 Neogene Species 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 108010072788 angiogenin Proteins 0.000 description 3
- 235000011089 carbon dioxide Nutrition 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 101150091879 neo gene Proteins 0.000 description 3
- 230000035479 physiological effects, processes and functions Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 229920001287 Chondroitin sulfate Polymers 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 102000016359 Fibronectins Human genes 0.000 description 2
- 101150003028 Hprt1 gene Proteins 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 241000208202 Linaceae Species 0.000 description 2
- 235000004431 Linum usitatissimum Nutrition 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 239000004809 Teflon Substances 0.000 description 2
- 229920006362 Teflon® Polymers 0.000 description 2
- 229920004933 Terylene® Polymers 0.000 description 2
- 102000006601 Thymidine Kinase Human genes 0.000 description 2
- 108020004440 Thymidine kinase Proteins 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229940059329 chondroitin sulfate Drugs 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 210000003953 foreskin Anatomy 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 210000004013 groin Anatomy 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007102 metabolic function Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000005020 polyethylene terephthalate Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000012207 quantitative assay Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 210000001626 skin fibroblast Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 229950004616 tribromoethanol Drugs 0.000 description 2
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- LCSKNASZPVZHEG-UHFFFAOYSA-N 3,6-dimethyl-1,4-dioxane-2,5-dione;1,4-dioxane-2,5-dione Chemical group O=C1COC(=O)CO1.CC1OC(=O)C(C)OC1=O LCSKNASZPVZHEG-UHFFFAOYSA-N 0.000 description 1
- 229920002955 Art silk Polymers 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000002734 Collagen Type VI Human genes 0.000 description 1
- 108010043741 Collagen Type VI Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 229920000544 Gore-Tex Polymers 0.000 description 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 description 1
- 101000664737 Homo sapiens Somatotropin Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000004140 Oncostatin M Human genes 0.000 description 1
- 108090000630 Oncostatin M Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241001505332 Polyomavirus sp. Species 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 241000282405 Pongo abelii Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000000274 adsorptive effect Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000003855 balanced salt solution Substances 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 229940064804 betadine Drugs 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical class CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 210000003321 cartilage cell Anatomy 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000000501 collagen implant Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000006552 constitutive activation Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 230000008713 feedback mechanism Effects 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000012595 freezing medium Substances 0.000 description 1
- 210000002592 gangliocyte Anatomy 0.000 description 1
- 102000018146 globin Human genes 0.000 description 1
- 108060003196 globin Proteins 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000006362 insulin response pathway Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000011229 interlayer Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- RFKMCNOHBTXSMU-UHFFFAOYSA-N methoxyflurane Chemical compound COC(F)(F)C(Cl)Cl RFKMCNOHBTXSMU-UHFFFAOYSA-N 0.000 description 1
- 229960002455 methoxyflurane Drugs 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 210000003360 nephrocyte Anatomy 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000003856 thermoforming Methods 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- YFDSDPIBEUFTMI-UHFFFAOYSA-N tribromoethanol Chemical compound OCC(Br)(Br)Br YFDSDPIBEUFTMI-UHFFFAOYSA-N 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/24—Collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L27/44—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2310/00—Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
- A61F2310/00005—The prosthesis being constructed from a particular material
- A61F2310/00365—Proteins; Polypeptides; Degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
- A61L2300/414—Growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/426—Immunomodulating agents, i.e. cytokines, interleukins, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/428—Vitamins, e.g. tocopherol, riboflavin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/64—Animal cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Botany (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Materials Engineering (AREA)
- Vascular Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Composite Materials (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Prostheses (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/548,002 US5965125A (en) | 1995-10-25 | 1995-10-25 | Hybrid matrix implants and explants |
| US08/548,002 | 1995-10-25 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1205613A CN1205613A (zh) | 1999-01-20 |
| CN1199567C true CN1199567C (zh) | 2005-05-04 |
Family
ID=24187023
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB961993243A Expired - Fee Related CN1199567C (zh) | 1995-10-25 | 1996-10-25 | 混合基质植入物和外植物 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US5965125A (enExample) |
| EP (1) | EP0917428A4 (enExample) |
| JP (1) | JP2000501299A (enExample) |
| CN (1) | CN1199567C (enExample) |
| AU (1) | AU706563B2 (enExample) |
| BR (1) | BR9611248A (enExample) |
| NO (1) | NO326107B1 (enExample) |
| NZ (1) | NZ321417A (enExample) |
| RU (1) | RU2201765C2 (enExample) |
| WO (1) | WO1997015195A1 (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101868298B (zh) * | 2007-07-06 | 2013-02-06 | 香港大学 | 基于胶原的微球及其制备方法和用途 |
| CN101448527B (zh) * | 2006-05-19 | 2013-12-18 | 香港大学 | 细胞-基质微球，制备方法和应用 |
Families Citing this family (112)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050186673A1 (en) * | 1995-02-22 | 2005-08-25 | Ed. Geistlich Soehne Ag Fuer Chemistrie Industrie | Collagen carrier of therapeutic genetic material, and method |
| GB9721585D0 (en) * | 1997-10-10 | 1997-12-10 | Geistlich Soehne Ag | Chemical product |
| US7112320B1 (en) | 1995-06-07 | 2006-09-26 | Andre Beaulieu | Solid wound healing formulations containing fibronectin |
| US6528483B2 (en) | 1995-06-07 | 2003-03-04 | André Beaulieu | Method of producing concentrated non-buffered solutions of fibronectin |
| US6419920B1 (en) | 1995-10-25 | 2002-07-16 | Trans Karyotic Therapies, Inc. | Hybrid matrix implants and explants |
| IL118376A0 (en) * | 1996-05-22 | 1996-09-12 | Univ Ben Gurion | Polysaccharide sponges for cell culture and transplantation |
| US6150164A (en) * | 1996-09-30 | 2000-11-21 | The Regents Of The University Of Michigan | Methods and compositions of a bioartificial kidney suitable for use in vivo or ex vivo |
| US7899511B2 (en) | 2004-07-13 | 2011-03-01 | Dexcom, Inc. | Low oxygen in vivo analyte sensor |
| US20050033132A1 (en) | 1997-03-04 | 2005-02-10 | Shults Mark C. | Analyte measuring device |
| US9155496B2 (en) | 1997-03-04 | 2015-10-13 | Dexcom, Inc. | Low oxygen in vivo analyte sensor |
| US20010007673A1 (en) * | 1999-11-12 | 2001-07-12 | Merrill Seymour Goldenberg | Sustained-release delayed gels |
| TW586934B (en) * | 1997-05-19 | 2004-05-11 | Sumitomo Pharma | Immunopotentiating composition |
| GB9718415D0 (en) * | 1997-08-29 | 1997-11-05 | Smithkline Beecham Plc | Formulation |
| US20050186283A1 (en) * | 1997-10-10 | 2005-08-25 | Ed. Geistlich Soehne Ag Fuer Chemistrie Industrie | Collagen carrier of therapeutic genetic material, and method |
| US6886568B2 (en) * | 1998-04-08 | 2005-05-03 | The Johns Hopkins University | Method for fabricating cell-containing implants |
| US6378527B1 (en) * | 1998-04-08 | 2002-04-30 | Chondros, Inc. | Cell-culture and polymer constructs |
| US7427602B1 (en) * | 1998-05-13 | 2008-09-23 | The Regents Of The University Of Michigan | Sustained DNA delivery from structural matrices |
| JP2002526508A (ja) * | 1998-09-21 | 2002-08-20 | イシス・イノベイシヨン・リミテツド | フィブリル |
| DK1163018T3 (da) * | 1999-03-19 | 2003-09-29 | Univ Michigan Technology Man W | Mineralisering og cellulær mønstring på biomaterialeoverflader |
| US6767928B1 (en) | 1999-03-19 | 2004-07-27 | The Regents Of The University Of Michigan | Mineralization and biological modification of biomaterial surfaces |
| US6662805B2 (en) * | 1999-03-24 | 2003-12-16 | The Johns Hopkins University | Method for composite cell-based implants |
| US6372494B1 (en) | 1999-05-14 | 2002-04-16 | Advanced Tissue Sciences, Inc. | Methods of making conditioned cell culture medium compositions |
| US6287340B1 (en) * | 1999-05-14 | 2001-09-11 | Trustees Of Tufts College | Bioengineered anterior cruciate ligament |
| ATE284674T1 (de) * | 1999-10-05 | 2005-01-15 | Transkaryotic Therapies Inc | Hybride matrizen und gemische davon |
| EP1099443A1 (en) | 1999-11-11 | 2001-05-16 | Sulzer Orthopedics Ltd. | Transplant/implant device and method for its production |
| WO2001065936A1 (en) * | 2000-03-06 | 2001-09-13 | Shah Kumarpal A | Method for immune switching |
| RU2180241C2 (ru) * | 2000-04-18 | 2002-03-10 | Государственное унитарное предприятие "Иммунопрепарат" | Ранозаживляющее средство |
| US7144729B2 (en) | 2000-09-01 | 2006-12-05 | Dfb Pharmaceuticals, Inc. | Methods and compositions for tissue regeneration |
| AR034262A1 (es) * | 2000-09-14 | 2004-02-18 | Transkaryotic Therapies Inc | Una composicion para proporcionar una mezcla fluida inyectable, un equipo, un metodo para preparacion de una mezcla de dicho equipo, un aparato para la introduccion de una mezcla en un paciente |
| US6538010B1 (en) * | 2000-11-08 | 2003-03-25 | Research Triangle Institute | Compounds and methods for promoting smoking cessation |
| US6444222B1 (en) * | 2001-05-08 | 2002-09-03 | Verigen Transplantation Services International Ag | Reinforced matrices |
| CA2388723C (en) * | 2001-06-06 | 2012-10-23 | Becton, Dickinson & Company | Method of providing a substrate with a ready-to-use, uniformly distributed extracellular matrix |
| EP1406573A4 (en) * | 2001-06-07 | 2005-03-30 | Skinmedica Inc | CONDITIONED CELL CULTURE MEDIA AND ITS USES |
| EP1416874A4 (en) * | 2001-07-16 | 2007-04-18 | Depuy Products Inc | BIOLOGICAL / SYNTHETIC POROUS EXTRACELLULAR HYBRID MATRIX SCUFF |
| JP4197160B2 (ja) * | 2001-07-16 | 2008-12-17 | デピュイ・プロダクツ・インコーポレイテッド | 軟骨修復および再生用の支持骨格材料および方法 |
| US8337537B2 (en) * | 2001-07-16 | 2012-12-25 | Depuy Products, Inc. | Device from naturally occurring biologically derived materials |
| AU2002320517B2 (en) * | 2001-07-16 | 2008-03-13 | Depuy Products, Inc. | Hybrid biologic-synthetic bioabsorable scaffolds |
| US6867189B2 (en) * | 2001-07-26 | 2005-03-15 | Genset S.A. | Use of adipsin/complement factor D in the treatment of metabolic related disorders |
| US7217570B2 (en) * | 2001-08-23 | 2007-05-15 | The Wistar Institute Of Anatomy And Biology | Organotypic intestinal culture and methods of use thereof |
| US7332330B2 (en) * | 2001-09-11 | 2008-02-19 | Renamed Biologics, Inc. | Device for maintaining vascularization near an implant |
| US20040031067A1 (en) * | 2001-10-11 | 2004-02-12 | Meenhard Herlyn | Regulation of human skin healing |
| US20030166274A1 (en) * | 2001-11-15 | 2003-09-04 | Hewitt Charles W. | Three-dimensional matrix for producing living tissue equivalents |
| US6902932B2 (en) * | 2001-11-16 | 2005-06-07 | Tissue Regeneration, Inc. | Helically organized silk fibroin fiber bundles for matrices in tissue engineering |
| RU2210352C1 (ru) * | 2001-12-07 | 2003-08-20 | Глинских Нина Поликарповна | Композиция для лечения воспалительных заболеваний пародонта на основе клеточных культур |
| RU2210341C1 (ru) * | 2001-12-07 | 2003-08-20 | Глинских Нина Поликарповна | Способ получения трансплантатов для заполнения костных дефектов при хирургическом лечении воспалительных заболеваний пародонта |
| US7803393B2 (en) * | 2002-03-08 | 2010-09-28 | Board Of Regents, The University Of Texas System | Preparing an implant by gas-plasma treatment of a substrate to couple cells |
| US7442546B2 (en) * | 2002-03-15 | 2008-10-28 | The Regents Of The University Of Michigan | Method of modulating inflammatory response |
| US7431922B2 (en) * | 2002-03-29 | 2008-10-07 | Tissuegene, Inc. | Bioadhesive directed somatic cell therapy |
| US20040219659A1 (en) * | 2002-04-22 | 2004-11-04 | Altman Gregory H. | Multi-dimensional strain bioreactor |
| US7459152B2 (en) * | 2003-04-23 | 2008-12-02 | Rush University Medical Center | Erythropoietin administration to improve graft survival |
| US7651596B2 (en) | 2005-04-08 | 2010-01-26 | Dexcom, Inc. | Cellulosic-based interference domain for an analyte sensor |
| US7591801B2 (en) | 2004-02-26 | 2009-09-22 | Dexcom, Inc. | Integrated delivery device for continuous glucose sensor |
| RU2249462C1 (ru) * | 2003-08-21 | 2005-04-10 | Севастьянов Виктор Иванович | Универсальный гетерогенный коллагеновый матрикс для имплантации и способ его получения |
| US7920906B2 (en) | 2005-03-10 | 2011-04-05 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
| US8257963B2 (en) | 2007-06-01 | 2012-09-04 | Depuy Mitek, Inc. | Chondrocyte container and method of use |
| US7897384B2 (en) * | 2003-09-08 | 2011-03-01 | Ethicon, Inc. | Chondrocyte therapeutic delivery system |
| US7927599B2 (en) * | 2003-09-08 | 2011-04-19 | Ethicon, Inc. | Chondrocyte therapeutic delivery system |
| AU2004276316A1 (en) * | 2003-09-24 | 2005-04-07 | The Board Of Trustees Of The Leland Stanford Junior University | IGF-1 instructs multipotent adult CNS neural stem cells to an oligodendroglial lineage |
| US9247900B2 (en) | 2004-07-13 | 2016-02-02 | Dexcom, Inc. | Analyte sensor |
| US11633133B2 (en) | 2003-12-05 | 2023-04-25 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
| US8423114B2 (en) | 2006-10-04 | 2013-04-16 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
| EP2239566B1 (en) | 2003-12-05 | 2014-04-23 | DexCom, Inc. | Calibration techniques for a continuous analyte sensor |
| US8808228B2 (en) | 2004-02-26 | 2014-08-19 | Dexcom, Inc. | Integrated medicament delivery device for use with continuous analyte sensor |
| RU2268738C1 (ru) * | 2004-06-18 | 2006-01-27 | Владимир Никитич Ярыгин | Способ восстановления гиалинового хряща суставов |
| US7310544B2 (en) | 2004-07-13 | 2007-12-18 | Dexcom, Inc. | Methods and systems for inserting a transcutaneous analyte sensor |
| US20070045902A1 (en) | 2004-07-13 | 2007-03-01 | Brauker James H | Analyte sensor |
| ES2432556T3 (es) | 2004-08-04 | 2013-12-04 | Evonik Corporation | Métodos para fabricar dispositivos de suministro y sus dispositivos |
| WO2006073514A2 (en) * | 2004-08-25 | 2006-07-13 | Tufts University | Compositions, methods and kits for repressing virulence in gram positive bacteria |
| AU2006204461C1 (en) * | 2005-01-06 | 2012-01-12 | Baxter Healthcare S.A. | Supplemented matrices for the repair of bone fractures |
| US8744546B2 (en) | 2005-05-05 | 2014-06-03 | Dexcom, Inc. | Cellulosic-based resistance domain for an analyte sensor |
| US9107917B2 (en) * | 2005-05-13 | 2015-08-18 | The Feinstein Institute For Medical Research | Treatment of sepsis and inflammation with alpha2A adrenergic antagonists |
| JP2009508596A (ja) | 2005-09-19 | 2009-03-05 | ヒストジェニックス コーポレイション | 細胞支持基材及びその調製方法 |
| US20070148144A1 (en) * | 2005-10-27 | 2007-06-28 | Mason James M | Gene-enhanced tissue engineering |
| US9757061B2 (en) | 2006-01-17 | 2017-09-12 | Dexcom, Inc. | Low oxygen in vivo analyte sensor |
| EP2032149A4 (en) * | 2006-06-13 | 2010-09-01 | Fmc Biopolymer As | METHOD AND SYSTEMS FOR THE USE OF BIOPOLYMER-BASED BEADS AND HYDROGELS |
| KR100803576B1 (ko) | 2006-06-14 | 2008-02-15 | 주식회사 인피트론 | 지방줄기세포 및 지방세포를 포함한 이식용 조성물 |
| KR20070122316A (ko) * | 2006-06-26 | 2007-12-31 | (주) 에스바이오메딕스 | 주사용 인체 연조직 충전제 및 이의 제조 방법 |
| KR20070122315A (ko) * | 2006-06-26 | 2007-12-31 | (주) 에스바이오메딕스 | 자가 진피 세포 및 히알루론산을 함유하는 주사용 인체연조직 충전제 조성물 |
| US8735154B2 (en) * | 2006-10-30 | 2014-05-27 | The University Of Kansas | Templated islet cells and small islet cell clusters for diabetes treatment |
| US20080306444A1 (en) | 2007-06-08 | 2008-12-11 | Dexcom, Inc. | Integrated medicament delivery device for use with continuous analyte sensor |
| US9452258B2 (en) | 2007-10-09 | 2016-09-27 | Dexcom, Inc. | Integrated insulin delivery system with continuous glucose sensor |
| KR100956267B1 (ko) * | 2007-12-12 | 2010-05-07 | 주식회사 에이프로테크놀로지 | 엘라스틴을 안정화제로서 함유하는 반유동성 이식용 조성물 |
| WO2009078022A2 (en) * | 2007-12-17 | 2009-06-25 | Izun Pharmaceuticals Corporation | Synergistic combinations of growth factors with herbal compositions for the enhancement of tissue repair |
| US8728528B2 (en) | 2007-12-20 | 2014-05-20 | Evonik Corporation | Process for preparing microparticles having a low residual solvent volume |
| US9402724B2 (en) * | 2008-05-12 | 2016-08-02 | Mo-Sci Corporation | Dynamic bioactive nanofiber scaffolding |
| KR102018475B1 (ko) | 2008-09-15 | 2019-09-04 | 제넨테크, 인크. | 세포 오스몰농도를 조절하기 위한 조성물 및 방법 |
| US9889230B2 (en) * | 2008-10-17 | 2018-02-13 | Covidien Lp | Hemostatic implant |
| US9308070B2 (en) | 2008-12-15 | 2016-04-12 | Allergan, Inc. | Pliable silk medical device |
| GB0912399D0 (en) * | 2009-07-16 | 2009-08-26 | Ucl Business Plc | Polymeric collagen biomaterials |
| RU2449799C2 (ru) * | 2009-10-30 | 2012-05-10 | Федеральное Государственное Учреждение "Российский кардиологический научно-производственный комплекс Федерального агентства по высокотехнологичной медицинской помощи" | Средство для осуществления терапевтического ангиогенеза и способ его осуществления |
| WO2011113446A1 (en) * | 2010-03-17 | 2011-09-22 | Amsilk Gmbh | Method for production of polypeptide containing fibres |
| US8597948B2 (en) | 2011-03-10 | 2013-12-03 | First Principles, Inc. | Cloned biological material medical device and method thereof |
| WO2012145594A2 (en) * | 2011-04-20 | 2012-10-26 | Trustees Of Tufts College | Molded regenerated silk geometries using temperature control and mechanical processing |
| KR101327630B1 (ko) * | 2012-03-05 | 2013-11-13 | 울산대학교 산학협력단 | 아텔로콜라겐을 이용한 췌도세포 이식용 담체의 제조방법 그리고 이를 이용하여 제조된 인공췌장 |
| AU2014262670B2 (en) * | 2013-05-08 | 2020-07-09 | ProKidney IPCo, LLC | Organoids comprising isolated renal cells and uses thereof |
| US11229789B2 (en) | 2013-05-30 | 2022-01-25 | Neurostim Oab, Inc. | Neuro activator with controller |
| US10016600B2 (en) | 2013-05-30 | 2018-07-10 | Neurostim Solutions, Llc | Topical neurological stimulation |
| US10077420B2 (en) | 2014-12-02 | 2018-09-18 | Histogenics Corporation | Cell and tissue culture container |
| US9238090B1 (en) | 2014-12-24 | 2016-01-19 | Fettech, Llc | Tissue-based compositions |
| US11077301B2 (en) | 2015-02-21 | 2021-08-03 | NeurostimOAB, Inc. | Topical nerve stimulator and sensor for bladder control |
| US10973956B2 (en) | 2017-01-05 | 2021-04-13 | The Regents Of The University Of Michigan | Microporous hydrogel scaffolds for cell transplantation |
| US20190117131A1 (en) | 2017-10-24 | 2019-04-25 | Dexcom, Inc. | Pre-connected analyte sensors |
| US11331022B2 (en) | 2017-10-24 | 2022-05-17 | Dexcom, Inc. | Pre-connected analyte sensors |
| WO2019094365A1 (en) | 2017-11-07 | 2019-05-16 | Neurostim Oab, Inc. | Non-invasive nerve activator with adaptive circuit |
| US20200399594A1 (en) * | 2018-02-22 | 2020-12-24 | Uvic Industry Partnerships Inc. | Morphogenic compound-releasing microspheres and use in bioink |
| CN108690205A (zh) * | 2018-05-28 | 2018-10-23 | 深圳市第二人民医院 | 一种ⅱ型胶原和聚丙烯酰胺复合水凝胶及其制备和应用 |
| RU2722744C1 (ru) * | 2019-03-26 | 2020-06-03 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр реабилитации и курортологии" Министерства здравоохранения Российской Федерации (ФГБУ НМИЦ РК Минздрава России) | Органоспецифический биопластический материал на основе растворимой формы стабилизированного внеклеточного матрикса |
| KR20220025834A (ko) | 2019-06-26 | 2022-03-03 | 뉴로스팀 테크놀로지스 엘엘씨 | 적응적 회로를 갖는 비침습적 신경 활성화기 |
| WO2021126921A1 (en) | 2019-12-16 | 2021-06-24 | Neurostim Solutions, Llc | Non-invasive nerve activator with boosted charge delivery |
| CN111203115B (zh) * | 2020-01-07 | 2022-02-11 | 天津市第三中心医院 | 一种氧化多糖抗凝涂层血液透析膜材料及其制备方法 |
| WO2021210026A1 (en) * | 2020-04-17 | 2021-10-21 | Vasanthi Palanivel | A cell-free growth factor concentrate, method of preparing the same and a kit thereof |
| CN115785256A (zh) * | 2022-11-09 | 2023-03-14 | 武汉轻工大学 | 一种调控胶原与细胞受体结合能力的方法 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS55501130A (enExample) * | 1978-12-26 | 1980-12-18 | ||
| US4485096A (en) * | 1982-02-26 | 1984-11-27 | Massachusetts Institute Of Technology | Tissue-equivalent and method for preparation thereof |
| US4686098A (en) * | 1984-05-14 | 1987-08-11 | Merck & Co., Inc. | Encapsulated mouse cells transformed with avian retrovirus-bovine growth hormone DNA, and a method of administering BGH in vivo |
| US4604346A (en) * | 1984-10-09 | 1986-08-05 | Massachusetts Institute Of Technology | Skin-equivalent prepared by the use of punch biopsy |
| US4997753A (en) * | 1985-04-04 | 1991-03-05 | Verax Corporation | Weighted collagen microsponge for immobilizing bioactive material |
| US4863856A (en) * | 1985-04-04 | 1989-09-05 | Verax Corporation | Weighted collagen microsponge for immobilizing bioactive materials |
| US4861714A (en) * | 1985-04-04 | 1989-08-29 | Verax Corporation | Weighted collagen microsponge for immobilizing bioactive material |
| US5100783A (en) * | 1985-05-10 | 1992-03-31 | Verax Corporation | Weighted microsponge for immobilizing bioactive material |
| US5266480A (en) * | 1986-04-18 | 1993-11-30 | Advanced Tissue Sciences, Inc. | Three-dimensional skin culture system |
| US4963489A (en) * | 1987-04-14 | 1990-10-16 | Marrow-Tech, Inc. | Three-dimensional cell and tissue culture system |
| US5032508A (en) * | 1988-09-08 | 1991-07-16 | Marrow-Tech, Inc. | Three-dimensional cell and tissue culture system |
| EP0338716A3 (en) * | 1988-04-21 | 1990-04-11 | Berlex Laboratories, Inc. | Method and system for the production of non-degraded proteins from mammalian cells |
| US4837379A (en) * | 1988-06-02 | 1989-06-06 | Organogenesis Inc. | Fibrin-collagen tissue equivalents and methods for preparation thereof |
| NO910090L (no) * | 1988-07-11 | 1991-01-09 | Purdue Research Foundation | Vevstransplantat-sammensetning og metode. |
| IL90690A0 (en) * | 1988-09-30 | 1990-01-18 | Organogenesis Inc | Tissue equivalents and their preparation |
| US5106949A (en) * | 1989-09-15 | 1992-04-21 | Organogenesis, Inc. | Collagen compositions and methods for preparation thereof |
| IL95429A (en) * | 1989-09-15 | 1997-09-30 | Organogenesis | Living tissue equivalents comprising hydrated collagen lattice and a collagen gel and their production |
| US5032550A (en) | 1989-10-13 | 1991-07-16 | Aluminum Company Of America | High impact resistant ceramic composite |
| US5256418A (en) * | 1990-04-06 | 1993-10-26 | Organogenesis, Inc. | Collagen constructs |
| US5270192A (en) * | 1991-02-07 | 1993-12-14 | Monsanto Company | Biological artificial liver |
| PT101031B (pt) * | 1991-11-05 | 2002-07-31 | Transkaryotic Therapies Inc | Processo para o fornecimento de proteinas por terapia genetica |
| RU2014359C1 (ru) * | 1992-02-12 | 1994-06-15 | Радюхин Виктор Алексеевич | Трехмерный биоактивный носитель для культивирования животных клеток и тканей |
| EP0674497B1 (en) * | 1992-11-16 | 2002-07-24 | Brown University Research Foundation | Microporous macrocapsules |
| TW402639B (en) * | 1992-12-03 | 2000-08-21 | Transkaryotic Therapies Inc | Protein production and protein delivery |
| FR2704236B1 (fr) * | 1993-04-21 | 1995-06-23 | Pasteur Institut | Vecteur rétroviral pour la préparation de cellules recombinantes susceptibles d'être implantées in vivo dans un but thérapeutique. |
| FR2708202B1 (fr) * | 1993-07-26 | 1996-03-29 | Pasteur Institut | Implant biocompatible pour l'expression chez l'homme ou chez l'animal de substances déterminées. |
| DK0702723T3 (da) * | 1993-04-21 | 2003-01-13 | Pasteur Institut | Biokompatibelt implantat til ekspression og udskillelse af terapeutisk forbindelse in vivo |
| DE69533437T2 (de) * | 1994-01-13 | 2005-09-15 | The Rogosin Institute | Makroeingekapselte sekretorische zellen |
| JPH10501706A (ja) * | 1994-04-04 | 1998-02-17 | コラーゲン コーポレイション | 細胞−ゲル |
-
1995
- 1995-10-25 US US08/548,002 patent/US5965125A/en not_active Expired - Fee Related
-
1996
- 1996-10-25 BR BR9611248-4A patent/BR9611248A/pt not_active Application Discontinuation
- 1996-10-25 WO PCT/US1996/017114 patent/WO1997015195A1/en not_active Ceased
- 1996-10-25 RU RU98109891/14A patent/RU2201765C2/ru not_active IP Right Cessation
- 1996-10-25 AU AU74744/96A patent/AU706563B2/en not_active Ceased
- 1996-10-25 CN CNB961993243A patent/CN1199567C/zh not_active Expired - Fee Related
- 1996-10-25 NZ NZ321417A patent/NZ321417A/xx unknown
- 1996-10-25 JP JP9516803A patent/JP2000501299A/ja active Pending
- 1996-10-25 EP EP96936960A patent/EP0917428A4/en not_active Withdrawn
-
1998
- 1998-04-24 NO NO19981859A patent/NO326107B1/no not_active IP Right Cessation
-
1999
- 1999-05-14 US US09/312,246 patent/US6472181B1/en not_active Expired - Fee Related
-
2002
- 2002-07-02 US US10/188,628 patent/US6582391B2/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101448527B (zh) * | 2006-05-19 | 2013-12-18 | 香港大学 | 细胞-基质微球，制备方法和应用 |
| CN101868298B (zh) * | 2007-07-06 | 2013-02-06 | 香港大学 | 基于胶原的微球及其制备方法和用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| NO981859D0 (no) | 1998-04-24 |
| US20030077260A1 (en) | 2003-04-24 |
| NO981859L (no) | 1998-06-24 |
| EP0917428A1 (en) | 1999-05-26 |
| JP2000501299A (ja) | 2000-02-08 |
| CN1205613A (zh) | 1999-01-20 |
| US6582391B2 (en) | 2003-06-24 |
| EP0917428A4 (en) | 2002-09-18 |
| NZ321417A (en) | 2000-03-27 |
| AU7474496A (en) | 1997-05-15 |
| RU2201765C2 (ru) | 2003-04-10 |
| AU706563B2 (en) | 1999-06-17 |
| BR9611248A (pt) | 1999-12-28 |
| US6472181B1 (en) | 2002-10-29 |
| NO326107B1 (no) | 2008-09-22 |
| WO1997015195A1 (en) | 1997-05-01 |
| US5965125A (en) | 1999-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1199567C (zh) | 混合基质植入物和外植物 | |
| CN1214781C (zh) | 杂合基质和杂合基质混合物 | |
| JP4624566B2 (ja) | 高密度の細胞を産生および使用するための装置および方法およびそこからの産物 | |
| US6419920B1 (en) | Hybrid matrix implants and explants | |
| CN1137723C (zh) | 强化的用于加速伤口愈合的伤口覆盖物和组合物 | |
| CN1152938A (zh) | 对在生物人工器官中被囊细胞的生长控制 | |
| CN109568671A (zh) | 一种水凝胶负载细胞的3d骨修复支架及其制备方法 | |
| HK1040740A1 (zh) | 生物工程化的组织构建物、其制备方法及其应用 | |
| JP2003174897A (ja) | 相同組換えによる脊椎動物細胞等のトランスフェクション | |
| CN116925207B (zh) | 重组人源化胶原蛋白及其制备方法和应用 | |
| CN1533431A (zh) | 细胞移植的方法和试剂 | |
| CN1829791A (zh) | 皮肤再生系统 | |
| US5453270A (en) | Pharmaceutical composition and method for hypermetabolic weight loss | |
| Bakshi et al. | A chemotactic functional scaffold with VEGF-releasing peptide amphiphiles facilitates bone regeneration by BMP-2 in a large-scale rodent cranial defect model | |
| AU736255B2 (en) | Hybrid matrix implants and explants | |
| CN110306289A (zh) | 一种含有阿西替尼的纳米纤维电纺膜及其制备方法和应用 | |
| CN1655802A (zh) | 生物粘附性定向体细胞治疗 | |
| CN1837358A (zh) | 一种三维条件下扩增造血干细胞的方法 | |
| CN113444680A (zh) | 一种生物3d打印制备体外皮肤模型的方法 | |
| CN1772885A (zh) | 诱导干细胞向胰岛样细胞分化的方法及胰岛样细胞的应用 | |
| CA2235811C (en) | Hybrid matrix implants and explants | |
| CN1269963C (zh) | 心房肽基因转染细胞微囊 | |
| JP2022519313A (ja) | 緩衝液製剤の方法およびシステム | |
| CN1323348A (zh) | 猪促生长素传递系统 | |
| AU2005200275B2 (en) | Apparatus and methods for producing and using high-density cells and products therefrom |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20050504 Termination date: 20091125 |